Implementation of Long-Acting PrEP: Case-Based Panel Discussion With Clinicians


Colleen Kelley, MD, MPH
Emory University
Kim Scarsi, PharmD
University of Nebraska Medical Center
Hyman Scott, MD, MPH
University of California San Francisco


Jose Castillo-Mancilla, MD
University of Colorado Anschutz


June 28, 2022 - 10:00 AM


June 28, 2022 - 11:30 AM

Add to iCal Calendar


Assessment of Needs

This case-based panel webinar will discuss the anticipated barriers to the implementation of long-acting injectable preexposure prophylaxis (PrEP), which was approved by the US Food and Drug Administration in December 2021), key aspects of its clinical pharmacology, and the challenges in the diagnosis of HIV in patients on long-acting PrEP.

This webinar is part 2 of a 2-part webinar series on the updated PrEP guidelines. Part 1 provides a summary of the Latest Update to the PrEP Guidelines. 

Learning Objectives

At the end of this webinar, participants will be able to:

  • Identify how to address the challenges of implementing long-acting injectable PrEP in the clinic
  • Describe how to incorporate long-acting injectable PrEP into clinical practice
  • Identify the main drug-drug interactions of long-acting injectable PrEP
  • Understand the potential challenges in establishing a diagnosis of HIV in persons using long-acting injectable PrEP


Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, June 28, 2022, 9:00 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.


Dr Castillo-Mancilla has received grants/grant pending paid to his institution from Gilead Sciences, Inc. (Updated 01/17/22)


Dr Kelley has received grants/grants pending paid to her institution from Moderna, Inc., Novavax, Humanigen, Gilead Sciences, Inc., and ViiV Healthcare. (Updated 02/22/22)

Dr Scarsi has received grant/grants pending paid to her institution from Organon LLC. (Updated 01/28/22)

Dr Scott has no financial relationships with ineligible companies to disclose. (Updated 02/22/22)


Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22) 
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)


CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Janssen Therapeutics


Theratechnologies, Inc.


Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.